Skip to main content
Gossamer Bio, Inc. logo

Gossamer Bio, Inc. — Investor Relations & Filings

Ticker · GOSS ISIN · US38341P1021 LEI · 549300ZOC0N2W6PSFR58 US Manufacturing
Filings indexed 424 across all filing types
Latest filing 2025-10-02 Director's Dealing
Country US United States of America
Listing US GOSS

About Gossamer Bio, Inc.

https://www.gossamerbio.com/

Gossamer Bio, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of its lead investigational product, seralutinib. The company is developing this therapy for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). Seralutinib is an inhaled inhibitor of PDGFRα/β, CSF1R, and c-KIT, designed for delivery via a dry powder inhaler. The company's goal is to address the needs of patients with these rare diseases.

Recent filings

Filing Released Lang Actions
FORM 4
Director's Dealing
2025-10-02 English
FORM 4
Director's Dealing
2025-10-02 English
FORM 4
Director's Dealing
2025-10-02 English
FORM 4
Director's Dealing
2025-10-02 English
FORM 4
Director's Dealing
2025-10-02 English
8-K
Regulatory Filings
2025-09-25 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.